Fosun Pharma's subsidiary has committed USD 60 million upfront to secure an exclusive option over the global rights to AR1001, a Phase III oral PDE5 inhibitor being developed by South Korea's AriBio Co., Ltd. for Alzheimer's disease. The option and licence agreement, signed on May 13, expands Fosun Pharma Industrial's existing foothold in the asset — which already covers Greater China and ten Southeast Asian markets — to a near-worldwide territorial scope. If exercised following Phase III data, the deal could total up to USD 240 million in fixed and milestone payments, plus a royalty stream running 15 years per country from first commercialization.
Under the terms, the USD 60 million option fee is payable at signing and is non-refundable. Should Fosun Pharma elect to exercise the option — a decision it must make within 90 days of receiving complete topline data from the ongoing POLARIS-AD Phase III trial — it would pay a further USD 80 million upfront and become eligible for up to USD 100 million in regulatory milestone payments, for a combined upfront and regulatory total of up to USD 180 million. Sales milestones become payable once annual net sales in the licensed territories first reach USD 2.5 billion, though the individual tier amounts are not disclosed. Royalties are set at a low double-digit percentage of annual net sales, with reductions applicable if third-party licenses are required or competing products enter the market.
Deal context
AR1001 is an oral small-molecule candidate described by AriBio as a potent and highly selective PDE5 inhibitor. PDE5 inhibition elevates intracellular cyclic GMP levels; in the CNS context, this mechanism is hypothesized to enhance cerebral blood flow, reduce neuroinflammation, and support neuroprotection. Preclinical data cited by AriBio indicate the compound may clear amyloid plaques, inhibit abnormal tau phosphorylation, and suppress inflammatory responses, though the translation of these findings to clinical benefit remains to be established by the Phase III readout.
PDE5 inhibitors are a pharmacologically validated class — sildenafil and tadalafil are established drugs in cardiovascular and urological indications — but no agent in the class has received regulatory approval for Alzheimer's disease. AR1001 is therefore not first-in-class at the target level, but could be first-in-indication if POLARIS-AD succeeds. The trial is described as a global multicenter study in early Alzheimer's disease, enrolling patients ranging from mild cognitive impairment to mild dementia. A ClinicalTrials.gov identifier for POLARIS-AD was not disclosed in the filing.